Enzolytics, Inc. (OTC: ENZC) is a drug development company committed to the commercialization of its proprietary proteins for the treatment of debilitating infectious diseases. Immunotech is committed to creating drugs for the better health of mankind. Enzolytics is a 49% shareholder of IMMB BG.
Enzolytics’ flagship compound ITV-1 (Immune Therapeutic Vaccine-1) is a suspension of Inactivated Pepsin Fraction (IPF), which studies have shown is effective in the treatment of HIV/AIDS. IPF is the active drug substance of ITV-1 and is a purified extract of porcine pepsin. ITV-1 has been shown to modulate the immune system.
Electromedical Technologies, Inc. (OTC: EMED) is a commercial stage, FDA cleared, bioelectronic medical device manufacturing company initially focused on the treatment of various chronic, acute, intractable, and post-operative pain conditions. Through university collaboration agreements the company is working to develop a comprehensive research program in defining the effects of electro-modulation on the human body by studying the impacts of electrical fields in cell signaling and effects on virus assembly and immune responses with the goal of improving human wellbeing. The company’s current cleared product indications are for chronic acute post traumatic and post-operative, intractable pain relief.
Our animal studies do not involve any human testing, and are not related to our current products. We are conducting this research to augment and advance the science of electro-modulation in healthcare. The United States Food and Drug Administration has not reviewed or approved our animal research studies.
Goldman Small Cap Research Sets A $5.70 12-Month Price Target For Electromedical Technologies, Inc. (OTCQB: EMED) And Projects The Medical Device Company, Fo-cused On Chronic And Acute Pain Relief, Will Reach Volumes Of $1.55 Million In FY2021 And $17 Million In FY2022
Electromedical Technologies, Inc. (OTC: EMED) is poised to serve as a leading, broad- based chronic pain management bioelectronics provider. Leveraging its currently FDA-cleared flagship device that has a 10,000 unit installed base, EMED is set for clearance of a new device late next year that is smaller, cheaper, and with more capabilities including a telemedicine feature.
Bioelectronics is an important and developing field of “electronic” medicine which uses safe electrical impulses over the body’s neural circuitry to relieve pain, without drugs.
The Company’s innovative, affordable financial model also includes a novel telemedicine feature which, along with efficacy and ease of use, should drive new adoption. EMED’s recurring model includes a nominal down payment, monthly subscription fee, and a premium physician monitoring portal.
Our forecasts include 10,000 units sold upon introduction next year and a conservative 80,000 units sold in 2022, driving revenue to $17 million—which could prove to be conservative.
Even with a 12-month price target of $5.70, EMED’s shares are grossly undervalued. Our target is based on the low-end valuation of one of its comps in the peer group.
Voycare, Inc. (OTC: NAFS) is a California based telemedicine service provider and Chinese language digital health platform exclusively dedicated to women’s health in Asia, with the primary focus on China. Voycare is creating a new type of cross border health care experience for women by leveraging telehealth and the gig-economy, giving women a voice when making the right health care decision for themselves and their families. Voycare currently focuses on two important areas in women’s health, Counseling and Fertility. Founded in 2019, Voycare has offices in Los Angeles and Shanghai.